Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Sees Significant Decline in Short Interest

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the target of a significant drop in short interest in the month of June. As of June 15th, there was short interest totaling 191,896 shares, a drop of 39.3% from the May 31st total of 315,885 shares. Currently, 1.1% of the company’s stock are sold short. Based on an average daily trading volume, of 6,417,679 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Trading of Genenta Science

Several institutional investors have recently bought and sold shares of the company. Eurizon Capital SGR S.p.A. purchased a new position in Genenta Science in the fourth quarter worth about $536,000. Ghisallo Capital Management LLC bought a new stake in shares of Genenta Science during the fourth quarter valued at approximately $482,000. Weiss Asset Management LP bought a new stake in shares of Genenta Science during the fourth quarter valued at approximately $480,000. Norges Bank purchased a new position in Genenta Science in the 4th quarter worth approximately $337,000. Finally, Alyeska Investment Group L.P. purchased a new position in Genenta Science in the 4th quarter worth approximately $328,000. 15.13% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Genenta Science from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Genenta Science currently has an average rating of “Sell”.

Genenta Science Stock Performance

Shares of GNTA remained flat at $1.72 during mid-day trading on Friday. The stock had a trading volume of 91,847 shares, compared to its average volume of 382,343. The company has a quick ratio of 14.16, a current ratio of 14.16 and a debt-to-equity ratio of 0.35. The stock’s 50 day moving average is $1.23 and its 200-day moving average is $1.10. Genenta Science has a 12-month low of $0.55 and a 12-month high of $10.00.

About Genenta Science

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.